SCHEMBL6930381

SCHEMBL6930381

CC(C)CC(NCC(C(=O)O)c1cc(-c2ccccc2)on1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
PPARG P37231 2/20 0.41
PPARA Q07869 2/20 0.41
F2RL1 P55085 1/20 0.41
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD1 P21728 1/20 0.40
SLC6A2 P23975 1/20 0.40
ADRA1A P35348 1/20 0.40
OPRM1 P35372 1/20 0.40
DRD3 P35462 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
MME P08473 1/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5869312 1.00 ALDH1A1 (0.42) ALDH1A1PPARGPPARAF2RL1NPC1
SCHEMBL7421359 0.91 THRB (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2MME
SCHEMBL7419197 0.88 NPC1 (0.54) ALDH1A1NPC1RAB9ASMN1; SMN2MME
SCHEMBL7425314 0.87 HPGD (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL7383800 0.83 PPARG (0.39) ALDH1A1PPARGPPARAMAPTMEN1
SCHEMBL7416089 0.78 ALOX5 (0.44) MME
SCHEMBL1655302 0.78 CTSK (0.62) NPC1RAB9ASMN1; SMN2MMEMAPT
SCHEMBL7428133 0.77 HDAC1 (0.40) ALDH1A1PPARGPPARANPC1RAB9A
SCHEMBL7377704 0.77 GRN (0.43) ALDH1A1SMN1; SMN2MME
SCHEMBL7378949 0.76 MME (0.50) ALDH1A1MMELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002039997-A2 ACE-2 MODULATING COMPOUNDS AND USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-05-23 WO claimed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed
WO-2002039997-A2 ACE-2 MODULATING COMPOUNDS AND USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof ACE, ACE2, AGTR2 ALDH1A1 1305/4885PPARG 393/4885PPARA 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.